Amikacin

• A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-assoc… Pending
  2023-510075-63-00 Phase III 1 country Centre Hospitalier Regional Universitaire De Tours
• BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis Pending
  2024-516849-39-01 Phase III 1 country Assistance Publique Hopitaux De Paris
• Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile … Pending
  2025-524264-38-00 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
• Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized… Recruiting
  2023-508441-41-00 Phase IV 1 country Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevil…
• AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe… Recruiting
  2023-506843-40-00 Phase III 1 country Centre Hospitalier Universitaire Amiens Picardie
• Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia: A randomized, non-blinded, no… Recruiting
  2024-519186-21-01 Phase IV 1 country Hvidovre Hospital
• A Study of Aztreonam-Avibactam (ATM-AVI) Compared to Best Available Therapy in Pediatric Participants with Serious Gram-Negative Bacterial C… Recruiting
  2022-501575-12-00 Phase II 4 countries Pfizer Inc.
• Finding the best treatment for lung disease from infection with Mycobacterium abscessus Recruiting
  2023-506575-99-00 Phase II 1 country The University Of Queensland
• A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused … Ended
  2023-505273-33-00 Phase III 11 countries Insmed Inc.

Showing 1–9 of 9 trials